Tritanrix HB

Description

Diphtheria, Tetanus, Pertussis (whole cell) and Hepatitis B (rDNA) vaccine (adsorbed)

Tritanrix™ HB contains Diphtheria (D), Tetanus (T) toxoids, inactivated whole cell Pertussis bacteria (Pw) and the purified major surface antigen of the rec Hepatitis B virus (HBV), adsorbed on aluminium salts. This tetravalent combination vaccine is administered for active immunization against Diphtheria, Tetanus, Pertussis (whooping cough) and Hepatitis B.

Immunization guideline:

The recommended dose (0.5 ml) of the vaccine must be administered.

Primary vaccination schedule consists of three doses within the first six months of life. Following the monovalent HepB dose at birth, vaccination with the Tritanrix HB combined vaccine should start at 6 weeks of age. Three vaccine doses must be administered at intervals of at least 4 weeks. In the case of children born of known HB carrier mothers the immunoprophylactic measures for hepatitis B should not be modified. This may require separate vaccination with HB and DTwP vaccines and also include the administration of HBIg at birth.

Booster vaccination: It has been shown that Tritanrix™ HB can be safely administered as a booster dose during the second year of life. However, requirement of Hep B Booster is not yet established. DTP boosters (without Hep B) are recommended before the end of 2nd year of life and at 4-6 years of age.

For latest IAP updates see revised immunization schedule.

Additional information

manufacturer

GlaxoSmithKline

country-of-manufacture

Belgium

vaccine-type

Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B

pharmaceutical-form

Liquid

package-size

1 Dose

route-of-administration

Intramuscular

preservative

Thiomersal

Contraindications

Tritanrix™ HB should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis or HB vaccines. Tritanrix ™ HB is contra-indicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine. In these circumstances the vaccination course should be continued with DT and HB vaccines.